Literature DB >> 10498392

Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.

J L Hopper1, M C Southey, G S Dite, D J Jolley, G G Giles, M R McCredie, D F Easton, D J Venter.   

Abstract

The average breast cancer risk for carriers of a germ-line mutation in BRCA1 or BRCA2 (penetrance) has been estimated from the multiple-case families collected by the Breast Cancer Linkage Consortium (BCLC) to be approximately 80% to age 70. However, women now being tested for these mutations do not necessarily have the intense family history of the BCLC families. Testing for protein-truncating mutations in exons 2, 11, and 20 of BRCA1 and exons 10 and 11 of BRCA2 was conducted in a population-based sample of 388 Australian women with breast cancer diagnosed before age 40. Onset of breast cancer was analyzed in the known and potential mutation-carrying first- and second-degree female relatives of cases found to carry a mutation. Of the 18 mutation-carrying cases (9 BRCA1 and 9 BRCA2), only 5 (1 BRCA1 and 4 BRCA2) had at least one affected relative, so family history of breast cancer was not a strong predictor of mutation status in this setting. The risk in mutation carriers was, on average, 9 times the population risk [95% confidence interval (CI), 4-23; P < 0.001]. Penetrance to age 70 was 40% (95% CI, 15-65%), about half that estimated from BCLC families. By extrapolation, approximately 6% (95% CI, 2-20%) of breast cancer before age 40 may be caused by protein-truncating mutations in BRCA1 or BRCA2. Breast cancer risk in BRCA1 or BRCA2 mutation carriers may be modified by other genetic or environmental factors. Genetic counselors may need to take into account the family history of the consultand.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498392

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  76 in total

1.  Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2.

Authors:  J L Hopper; M A Jenkins
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.

Authors:  J Cui; A C Antoniou; G S Dite; M C Southey; D J Venter; D F Easton; G G Giles; M R McCredie; J L Hopper
Journal:  Am J Hum Genet       Date:  2000-12-27       Impact factor: 11.025

3.  Segregation analyses of 1,476 population-based Australian families affected by prostate cancer.

Authors:  J Cui; M P Staples; J L Hopper; D R English; M R McCredie; G G Giles
Journal:  Am J Hum Genet       Date:  2001-04-11       Impact factor: 11.025

4.  The effect of disease penetrance, family size, and age of onset on family history with application to setting eligibility criteria for genetic testing.

Authors:  Alexandre Sibert; David E Goldgar
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

5.  BRCA2 T2722R is a deleterious allele that causes exon skipping.

Authors:  James D Fackenthal; Luca Cartegni; Adrian R Krainer; Olufunmilayo I Olopade
Journal:  Am J Hum Genet       Date:  2002-07-19       Impact factor: 11.025

6.  Firing up the nature/nurture controversy: bioethics and genetic determinism.

Authors:  I de Melo-Martín
Journal:  J Med Ethics       Date:  2005-09       Impact factor: 2.903

Review 7.  Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer.

Authors:  Mark A Jenkins; Melissa C Southey; Graham G Giles; John L Hopper
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

8.  Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer.

Authors:  Ee Ming Wong; Melissa C Southey; Stephen B Fox; Melissa A Brown; James G Dowty; Mark A Jenkins; Graham G Giles; John L Hopper; Alexander Dobrovic
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-26

9.  Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.

Authors: 
Journal:  Breast Cancer Res Treat       Date:  2007-10-31       Impact factor: 4.872

Review 10.  Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.

Authors:  Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.